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subsequently underreported. We re-
commend to carefully examine the skin
of patients, particular with red hair or a
fair skin color, for the presence of
nonpigmented, white to pale red ma-
cules with a silvery ‘‘shining’’ when
observed with tangential light.
Finally, although our single case
does not allow definitive conclusions
about the association of MC1R poly-
morphism with ‘‘white’’ nevi and ‘‘red’’
melanomas, it represents an interesting
observation for future investigations.
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TO THE EDITOR
Organ transplant recipients (OTRs)
have an increased risk to develop
malignancies (Adami et al., 2003;
Villeneuve et al., 2007), especially skin
carcinomas like squamous-cell carci-
noma (SCC) and basal-cell carcinoma
(BCC; Hartevelt et al., 1990; Bouwes
Bavinck et al., 1996; Bordea et al.,
2004). This increased risk is associated
with the immunosuppressive therapy
needed to prevent graft rejection (For-
tina et al., 2004). Azathioprine, a
thiopurine drug, is widely used as an
immunosuppressant in OTRs. The abil-
ity of thiopurines to inhibit the prolif-
eration of activated T cells contributes
to the therapeutic immunosuppression
of azathioprine (Karran and Attard,
2008). However, one of the major
side effects of azathioprine is its ability
to incorporate into genomic DNA as a
thioguanine pseudobase, which is
thought to trigger the mismatch repair
(MMR) system. Continuous high levels of
incorporated 6-thioguanine leads to fail-
ure of the MMR system and subsequent
resistance to thiopurine treatment (Kar-
ran and Attard, 2008). Insufficient or
defective MMR leads to greatly increased
spontaneous mutation rates, that mani-
fest as microsatellite instability (MSI).
Presence of MSI is nowadays used as a
diagnostic tool for defective or insuffi-
cient MMR and is often seen in cancers
of the hereditary nonpolyposis colorectal
cancer (HNPCC) syndrome. However, it
also occurs in various sporadic cancers,
like colon, endometrial, and gastric
cancer (Boland et al., 1998).
Previous studies have shown that
acute myeloid leukemia (AML) and
sebaceous gland carcinoma (SGC) of
OTRs on long-term azathioprine treat-
ment display MSI (Harwood et al.,
2001; Offman et al., 2004). These
results contrasted to those found in
immunocompetent patients where
AMLs and (non-Muir-Torre related)
SGCs are microsatellite stable (Rimsza
et al., 2000; Harwood et al., 2001). As
less than 5% of the cutaneous SCCs and
BCCs in immunocompetent patients
display MSI (Quinn et al., 1995; Gray
et al., 2006; Saetta et al., 2007), we
hypothesized that cutaneous skin carci-
nomas of this specific group of patients
might display MSI as a result of the
azathioprine treatment. This could also
be a possible explanation for the higher
incidence of SCCs observed in
azathioprine- using OTRs compared to
OTRs on other drugs (Ulrich and Stock-
fleth, 2007; Crespo-Leiro et al., 2008).
To investigate this hypothesis, we
collected formalin-fixed paraffin-
embedded tumor material of 20 SCCs
Abbreviations: AML, acute myeloid leukemia; BCC, basal-cell carcinoma; HNPCC, hereditary
nonpolyposis colorectal cancer; MMR, mismatch repair; MSI, microsatellite instability; OTR, organ
transplant recipients; SCC, squamous-cell carcinoma; SGC, sebaceous gland carcinoma
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(20 azathioprine-treated OTRs) and 7
BCCs (5 azathioprine-treated OTRs)
available from the pathology archives
of the Leiden University Medical Cen-
ter. From three OTRs material from
both SCC and BCC were available
(detailed sample information in Table
S1). All samples were handled in a
coded fashion, following the medical
ethical guidelines described in the
Code ‘‘Proper Secondary Use of Hu-
man Tissue’’ established by the Dutch
Federation of Medical Sciences. Tumor-
rich parts were isolated from the
paraffin-embedded material by taking
tissue punches (diameter, 0.6 mm) with
a tissue microarrayer (Beecher Instru-
ments Inc.) on the basis of a Hematox-
ylin and Eosin-stained slide. DNA was
isolated using the RecoverAll Total
Nucleic Acid Isolation Kit (Ambion
Inc.). Five fluorescently labeled mono-
nucleotide repeat markers NR-21, BAT-
26, BAT-25, NR-24, and MONO-27
and two pentanucleotide repeat mar-
kers, Penta C and Penta D, were coam-
plified using the MSI Analysis System,
version 1.2 (Promega). These markers
were selected based on previous studies
(de la Chapelle, 1999; Offman et al.,
2004). Data were analyzed on ABI3300
(Applied Biosystems) using the Gene-
Scan Analysis and Genotyper software.
As normal tissue of the patients was not
available, we compared the profiles of
the five mononucleotide repeat markers
of the tumors to the profiles of a
microsatellite stable control sample,
human leukemia cell line K652
(Figure 1a), and a microsatellite instable
colon carcinoma of an HNPCC patient
(Figure 1b).
None of the 20 SCCs and 7 BCCs of
the 22 azathioprine-treated OTRs de-
monstrated MSI. All tumors showed a
profile of the microsatellite markers that
was similar to the microsatellite stable
control (Figure 1c–e).
To our knowledge this is the first
study to examine the presence of MSI in
SCCs and BCCs of azathioprine-treated
OTRs. Previous studies showed a high
prevalence of MSI in AMLs and SGCs of
azathioprine-treated OTRs, in contrast
to what is seen in tumors from
immunocompetent patients. Our results
showed that all tested tumors were
microsatellite stable, similar to SCCs
of immunocompetent patients (Rimsza







Figure 1. Profiles of the five mononucleotide markers tested. The K652 control sample displayed a microsatellite stable profile (a), whereas the HNPCC
control sample (b) clearly demonstrated instability of all five mononucleotides. Three SCCs (c–e), which are representative of all the tested SCCs
and BCCs, display the same microsatellite stable profile as the microsatellite stable control (a). The different mononucleotide repeat markers are
indicated in (a).
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Even the highly MSI-sensitive markers,
BAT-25 and BAT-26 (de la Chapelle,
1999), did not show any instability.
Therefore, we conclude that failure of
MMR system does not seem to be
involved in the development of skin
carcinomas in OTRs. Most likely the
role of azathioprine in the development
of skin carcinomas is different com-
pared to its role in AML and SGCs.
UV exposure is the important risk
factor for the development of skin
carcinoma in immunocompetent pa-
tients, whereas in OTRs the immuno-
suppression by medication is an
important cofactor (Boyle et al., 1984;
Bouwes Bavinck et al., 2007). It is
possible that the pressure of azathio-
prine on the MMR system is drowned
out by the combination of these two
risk factors: UV DNA damage will put
most pressure on the nucleotide exci-
sion repair. It is known that azathio-
prine has direct carcinogenic effects
(Karran and Attard, 2008). A recent
study by O’Donovan et al. showed that
the combination of UVA and azathio-
prine resulted in an increased level of
oxidative stress leading to highly muta-
genic oxidative DNA damage (O’Don-
ovan et al., 2005). Future studies are
needed to investigate whether this
mechanism also contributes to the
high incidence of skin carcinoma, in
particular SCCs, in OTRs using
azathioprine.
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Table S1. Characteristics of every collected SCC
and BCC.
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